Skip to main content
Canna~Fangled Abstracts

The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation

By February 4, 2022February 22nd, 2022No Comments


Review

doi: 10.3389/fphar.2021.806417. eCollection 2021.

Affiliations 

Abstract

Microglia, the resident immune cells of the brain, can take on a range of pro- or anti-inflammatory phenotypes to maintain homeostasis. However, the sustained activation of pro-inflammatory microglia can lead to a state of chronic neuroinflammation characterized by high concentrations of neurotoxic soluble factors throughout the brain. In healthy brains, the inflammatory processes cease and microglia transition to an anti-inflammatory phenotype, but failure to halt the pro-inflammatory processes is a characteristic of many neurological disorders. The endocannabinoid system has been identified as a promising therapeutic target for chronic neuroinflammation as there is evidence that synthetic and endogenously produced cannabinoids temper the pro-inflammatory response of microglia and may encourage a switch to an anti-inflammatory phenotype. Activation of cannabinoid type 2 (CB2) receptors has been proposed as the mechanism of action responsible for these effects. The abundance of components of the endocannabinoid system in microglia also change dynamically in response to several brain pathologies. This can impact the ability of microglia to synthesize and degrade endocannabinoids or react to endogenous and exogenous cannabinoids. Cannabinoid receptors also participate in the formation of receptor heteromers which influences their function specifically in cells that express both receptors, such as microglia. This creates opportunities for drug-drug interactions between CB2 receptor-targeted therapies and other classes of drugs. In this article, we review the roles of pro- and anti-inflammatory microglia in the development and resolution of neuroinflammation. We also discuss the fluctuations observed in the components of the endocannabinoid in microglia and examine the potential of CB2 receptors as a therapeutic target in this context.

Keywords: CB2 receptor; GPCR (G protein coupled receptor); MAPK signaling; endocannabinoid system; heteromer; microglia; neuroinflammation.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1

FIGURE 2

References

    1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., et al. (2002). Up-Regulation of the Inflammatory Cytokines IFN-Gamma and IL-12 and Down-Regulation of IL-4 in Cerebral Cortex Regions of APP(SWE) Transgenic Mice. J. Neuroimmunol 126, 50–57. 10.1016/s0165-5728(02)00050-4 – DOI – PubMed
    1. Alger B. E., Kim J. (2011). Supply and Demand for Endocannabinoids. Trends Neurosci. 34, 304–315. 10.1016/j.tins.2011.03.003 – DOI – PMC – PubMed
    1. Araujo D. J., Tjoa K., Saijo K. (2019). The Endocannabinoid System as a Window into Microglial Biology and its Relationship to Autism. Front Cel Neurosci 13, 424. 10.3389/fncel.2019.00424 – DOI – PMC – PubMed
    1. Ashton J. C., Glass M. (2007). The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration. Curr. Neuropharmacol 5, 73–80. 10.2174/157015907780866884 – DOI – PMC – PubMed
    1. Aso E., Juvés S., Maldonado R., Ferrer I. (2013). CB2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-like Phenotype in AβPP/PS1 Mice. J. Alzheimers Dis. 35, 847–858. 10.3233/JAD-130137 – DOI – PubMed

Publication types


Leave a Reply